WA/OR ACS Session I - Friday, June 16, 2017
Tumorigenicity
Migratory behavior
Extra tumor markers
Chemotherapy evasion
Higher rate of cancer recurrence
Higher rate of surgical site complications
Reduced survival
Increased hospital length of stay
0.5 mm
1 cm
5 mm
1 mm
5
10
15
20
Multifocal disease
Age >50
Invasive cancer
Unifocal DCIS
She reports that she will refuse adjuvant endocrine therapy.
Her tumor is estrogen receptor positive.
She has no palpable axillary lymph nodes.
She reports that she will refuse adjuvant chemotherapy.
The addition of chemotherapy to pre-operative radiation therapy improves overall survival.
There is overall survival benefit to preoperative versus postoperative chemoradiotherapy.
The addition of neoadjuvant systemic chemotherapy increases the rate of pathologic complete response.
Adherence to standard neoadjuvant chemoradiation treatment is independent of hospital geographic location.
Bowel prep
Surgeon experience
Neoadjuvant therapy
Radiation therapy
Medullary
Papillary
Anaplastic
Follicular
Quiz Review Timeline +
Our quizzes are rigorously reviewed, monitored and continuously updated by our expert board to maintain accuracy, relevance, and timeliness.